ContraVir Pharmaceuticals Inc. (CTRV) financial statements (2021 and earlier)

Company profile

Business Address 399 THORNALL STREET
EDISON, NJ 08837
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 313752
Cash and cash equivalents 313752
Prepaid expense 00010
Total current assets: 313852
Noncurrent Assets
Property, plant and equipment 00000
Intangible assets, net (including goodwill) 555 
Goodwill 222  
Intangible assets, net (excluding goodwill) 333  
Other undisclosed noncurrent assets 00000
Total noncurrent assets: 55500
TOTAL ASSETS: 8181352
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 13520
Accounts payable 12410
Accrued liabilities 11100
Debt 1 0  
Due to related parties     0
Total current liabilities: 33520
Noncurrent Liabilities
Liabilities, other than long-term debt 367 4
Deferred revenue and credits0    
Deferred tax liabilities, net011  
Business combination, contingent consideration, liability 333 
Derivative instruments and hedges, liabilities 022 4
Total noncurrent liabilities: 367 4
Total liabilities: 691225
Stockholders' equity
Stockholders' equity attributable to parent, including: 2913(3)
Common stock 00000
Additional paid in capital 776832172
Accumulated deficit (76)(60)(45)(28)(5)
Other undisclosed stockholders' equity attributable to parent 211414 
Total stockholders' equity: 2913(3)
TOTAL LIABILITIES AND EQUITY: 8181352

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Operating expenses (15)(21)(21)(14)(2)
Operating loss: (15)(21)(21)(14)(2)
Nonoperating income (expense)  44(0)(4)
Interest and debt expense (0)   (0)
Loss from continuing operations before equity method investments, income taxes: (15)(17)(17)(14)(5)
Other undisclosed income from continuing operations before income taxes 5    
Loss from continuing operations before income taxes: (10)(17)(17)(14)(5)
Income tax benefit 12   
Net loss attributable to parent: (9)(15)(17)(14)(5)
Preferred stock dividends and other adjustments    (8) 
Other undisclosed net income (loss) available to common stockholders, basic (8)   0
Net loss available to common stockholders, basic: (18)(15)(17)(22)(5)
Other undisclosed net loss available to common stockholders, diluted  (3)   
Net loss available to common stockholders, diluted: (18)(18)(17)(22)(5)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Net loss: (9)(15)(17)(14)(5)
Comprehensive loss, net of tax, attributable to parent: (9)(15)(17)(14)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: